Measures · D03 in 2017 · Part D · DD1 Drug Plan Customer Service
Appeals Upheld
AppealsDrug PlanSource: Independent Review Entity
- What it measures
- How often an Independent Reviewer thought the drug plan’s decision to deny an appeal was fair. This includes appeals made by plan members and out-of-network providers. (This rating is not based on how often the plan denies appeals, but rather how fair the plan is when they do deny an appeal.)
- How it's calculated
- This measure is defined as the percent of IRE confirmations of upholding the plans’ decisions. This is calculated as: [(Number of cases upheld) / (Total number of cases reviewed)] * 100. Total number of cases reviewed is defined all cases received by the IRE during the timeframe and receiving a decision before May 1, 2016. The denominator is equal to the number of cases upheld, fully reversed, and partially reversed. Dismissed, remanded, and withdrawn cases are not included in the denominator. Auto-forwarded cases are included, as these are considered to be adverse decisions per Subpart M rules. If a Reopening occurs and is decided prior to May 1, 2016, the Reopened decision is used in place of the Reconsideration decision. Reopenings decided on or after May 1, 2016 are not reflected in these data, the original decision result is used. The results of appeals that occur beyond Level 2 (i.e., Administrative Law Judge or Medicare Appeals Council appeals) are not included in the data. Contracts with no IRE cases reviewed will not receive a score in this measure.
- Data source
- Independent Review Entity (IRE) Data were obtained from the Independent Review Entity (IRE) contracted by CMS for Part D reconsiderations. The appeals used in this measure are based on the date they were received by the IRE, not the date a decision was reached by the IRE.
- Measurement period
- 01/01/2015 - 12/31/2015
- Better when
- Higher
- Weight
- 1.5 (Measures Capturing Access)
- Star assignment
- Clustering
- Case-mix adjusted
- —
- In improvement measure
- Yes
- Used in CAI
- No
- Exclusions
Show
Contracts with fewer than 10 cases reviewed by the IRE.
From the 2017 Star Ratings Technical Notes (CMS).
Cut points over time
Score needed to earn each star level. Part D thresholds differ for MA-PD and standalone PDP contracts.
2017 star distribution
Not rated: Not enough data available (274); Plan too new to be measured (76); Plan not required to report measure (13); No data available (8)
Cut point bands
| Star year | Org type | 1★ | 2★ | 3★ | 4★ | 5★ |
|---|---|---|---|---|---|---|
| 2021 | MA-PD | < 79 % | >= 79 % to < 85 % | >= 85 % to < 89 % | >= 89 % to < 95 % | >= 95 % |
| 2021 | PDP | < 80 % | >= 80 % to < 87 % | >= 87 % to < 93 % | >= 93 % to < 97 % | >= 97 % |
| 2020 | MA-PD | < 71% | ? 71% to < 78% | ? 78% to < 86% | ? 86% to < 94% | ? 94% |
| 2020 | PDP | < 80% | ? 80% to < 84% | ? 84% to < 90% | ? 90% to < 94% | ? 94% |
| 2019 | MA-PD | < 60% | ? 60% to < 69% | ? 69% to < 81% | ? 81% to < 92% | ? 92% |
| 2019 | PDP | < 64% | ? 64% to < 78% | ? 78% to < 89% | ? 89% to < 91% | ? 91% |
| 2018 | MA-PD | < 56% | ? 56% to < 71% | ? 71% to < 79% | ? 79% to < 89% | ? 89% |
| 2018 | PDP | < 61% | ? 61% to < 71% | ? 71% to < 81% | ? 81% to < 92% | ? 92% |
| 2017 | MA-PD | < 47% | ? 47% to < 66% | ? 66% to < 78% | ? 78% to < 88% | ? 88% |
| 2017 | PDP | < 60% | ? 60% to < 66% | ? 66% to < 77% | ? 77% to < 91% | ? 91% |
| 2016 | MA-PD | < 42% | ? 42% to < 60% | ? 60% to < 73% | ? 73% to < 88% | ? 88% |
| 2016 | PDP | < 54% | ? 54% to < 65% | ? 65% to < 76% | ? 76% to < 91% | ? 91% |
| 2015 | MA-PD | < 50% | ? 50% to < 60% | ? 60% to < 72% | ? 72% to < 84% | ? 84% |
| 2015 | PDP | < 48% | ? 48% to < 58% | ? 58% to < 68% | ? 68% to < 78% | ? 78% |
Lowest-scoring contracts, 2017
| Contract | Parent | Members | Score | Stars | Δ | Shortfall to 4★ | Pctile |
|---|---|---|---|---|---|---|---|
| H9412 Geisinger Gold | Risant Health, Inc. | 0 | 25 | 1 | — | 53 | 0% |
| S9701 Navitus MedicareRx | Medica Holding Company | 102,337 | 60 | 2 | — | 17 | 0% |
| H3924 Geisinger Gold | Risant Health, Inc. | 24,445 | 47 | 2 | +1 | 31 | 1% |
| H3954 Geisinger Gold | Risant Health, Inc. | 71,757 | 48 | 2 | +1 | 30 | 2% |
| H3813 Moda Health Plan, Inc. | Moda Partners, Inc. | — | 48 | 2 | — | 30 | 2% |
| H3347 Elderplan | Elderplan, Inc. | 27,294 | 50 | 2 | — | 28 | 3% |
| S2468 Blue Shield of California | California Physicians' Service | 44,382 | 64 | 2 | +1 | 13 | 4% |
| H2230 Blue Cross Blue Shield of Massachusetts | Blue Cross and Blue Shield of Massachusetts, Inc. | 45,136 | 51 | 2 | −1 | 27 | 4% |
| H5087 Wellcare | Centene Corporation | 12,465 | 53 | 2 | — | 25 | 5% |
| H5826 Community Health Plan of WA Medicare Advantage | Community Health Plan of Washington | 8,875 | 53 | 2 | — | 25 | 5% |
| H0504 Blue Shield of California | California Physicians' Service | 54,780 | 53 | 2 | −1 | 25 | 5% |
| H1302 Blue Cross of Idaho | Gemstone Holdings, Inc. | 3,795 | 57 | 2 | — | 21 | 7% |
| S0522 Symphonix Health Insurance, Inc. | UnitedHealth Group, Inc. | — | 66 | 3 | +1 | 11 | 7% |
| H1016 AvMed Medicare | Sentara Health Care (SHC) | — | 59 | 2 | −2 | 19 | 8% |
| H5859 CareOregon Advantage | CareOregon, Inc. | 13,070 | 60 | 2 | −1 | 18 | 9% |
| H3370 EMPIRE HEALTHCHOICE HMO, INC. | Anthem Inc. | — | 61 | 2 | −2 | 17 | 9% |
| H3204 Presbyterian Health Plan | Presbyterian Healthcare Services | 52,025 | 62 | 2 | — | 16 | 10% |
| E3014 Pennsylvania Public School Employees Retirement Sy | Commonwealth of PA Pub Schools Retirement System | 95,657 | 62 | 2 | −2 | 16 | 10% |
| S3875 Granite Alliance | Prime Therapeutics, LLC. | 0 | 68 | 3 | — | 9 | 11% |
| H5520 HEALTH NET LIFE INSURANCE COMPANY | Centene Corporation | — | 63 | 2 | 0 | 15 | 12% |
| H3957 Highmark Blue Cross Blue Shield or Highmark Blue Shield | Highmark Health | 81,837 | 66 | 3 | 0 | 12 | 13% |
| H3233 Premier Health Insuring Corporation | Premier Health Partners | — | 67 | 3 | — | 11 | 13% |
| H7245 Premera Blue Cross Medicare Advantage | Premera | — | 67 | 3 | — | 11 | 13% |
| S5975 Moda Health Plan, Inc. | Moda Partners, Inc. | 58,300 | 69 | 3 | −1 | 8 | 14% |
| H1112 Wellcare | Centene Corporation | 25,885 | 68 | 3 | 0 | 10 | 15% |
History
| Star year | Code | Name | Measured | Weight | Source |
|---|---|---|---|---|---|
| 2021 | D03 | Appeals Upheld | 01/01/2019 – 12/31/2019 | 2 | Independent Review Entity |
| 2020 | D03 | Appeals Upheld | 01/01/2018– 12/31/2018 | 1.5 | Independent Review Entity |
| 2019 | D03 | Appeals Upheld | 01/01/2017 – 12/31/2017 | 1.5 | Independent Review Entity |
| 2018 | D03 | Appeals Upheld | 01/01/2016 – 12/31/2016 | 1.5 | Independent Review Entity |
| 2017 | D03 | Appeals Upheld | 01/01/2015 - 12/31/2015 | 1.5 | Independent Review Entity |
| 2016 | D03 | Appeals Upheld | 01/01/2014 - 12/31/2014 | 1.5 | Independent Review Entity |
| 2015 | D02 | Appeals Upheld | 01/01/2014 - 06/30/2014 | 1.5 | Independent Review Entity |